Welcome to our dedicated page for Stevanato Group S P A news (Ticker: STVN), a resource for investors and traders seeking the latest updates and insights on Stevanato Group S P A stock.
Stevanato Group S.p.A. (NYSE: STVN) is a global provider of drug containment, drug delivery, and diagnostic solutions for pharmaceutical, biotechnology, and life sciences companies. Its news flow, as reflected in recent press releases and SEC filings, centers on financial performance, capacity expansion, financing arrangements, and participation in healthcare investor conferences.
Investors following STVN news will find regular quarterly earnings announcements detailing revenue trends, segment performance for the Biopharmaceutical and Diagnostic Solutions and Engineering segments, margin evolution, and the growing contribution of high-value solutions such as high-performance Nexa® syringes and EZ-fill® vials and cartridges. These updates often include discussion of non-GAAP measures, capital expenditures, and liquidity.
News coverage also highlights strategic investments and footprint optimization, including expansions at manufacturing facilities in Cisterna di Latina and Fishers to increase pre-filled syringe and ready-to-use cartridge capacity, and enhancements at the Bad Oeynhausen, Germany, site for drug delivery system production. Financing news, such as the €200 million agreements with BNL BNP Paribas, Cassa Depositi e Prestiti, and Banco BPM, provides additional context on how Stevanato Group funds these projects.
In addition, Stevanato Group frequently announces its participation in major healthcare and investor conferences in locations such as New York, London, Las Vegas, Chicago, and Vienna. These events offer further insight into management’s views on market dynamics, high-value solutions, and long-term strategy.
By monitoring this page, readers can track Stevanato Group’s latest earnings releases, operational updates on capacity expansion and optimization plans, financing developments, and investor relations activities, all drawn from company-issued news and regulatory communications.
Stevanato Group (NYSE: STVN) will release its fourth quarter and fiscal year 2022 financial results on March 2, 2023, at 6:30 a.m. ET. A conference call and webcast will follow at 8:30 a.m. ET, featuring a slide presentation available on the company’s Investor Relations site. Participants are encouraged to pre-register for expedited access. Dial-in options include +39 02 802 09 11 (Italy), +44 1 212 818004 (UK), and +1 718 705 8796 (USA). A replay of the webcast will be accessible for three months post-event, further enhancing transparency regarding the company’s performance.
Stevanato Group (NYSE: STVN), a global leader in drug containment, has announced a collaboration with Transcoject GmbH to introduce cyclic olefin polymer (COP) and cyclic olefin copolymer (COC) pre-fillable syringes (PFS). This new offering will enhance Stevanato’s existing glass PFS portfolio, enabling greater customization for clients across various applications, including sensitive biologics and mRNA vaccines. The partnership aims to leverage each company's expertise to provide a broad range of format options and increase operational efficiency. The new products will be introduced at the Pharmapack Europe conference in Paris on February 1-2, 2023.
Stevanato Group (NYSE: STVN) announced its participation in the Jefferies London Healthcare Conference scheduled for November 17, 2022, at 12:55 p.m. (GMT). The company, a global leader in drug containment, drug delivery, and diagnostic solutions, will provide a webcast available on its Investors section of the website. Founded in 1949, Stevanato Group supports the pharmaceutical and biotechnology sectors with a comprehensive portfolio of products and services throughout the drug life cycle.
Stevanato Group (NYSE: STVN) reported a strong third quarter of 2022 with a 14% revenue increase to €245.3 million. High-value solutions contributed 30% of total revenue, reflecting a growing shift in focus. The adjusted diluted EPS remained stable at €0.14, with an adjusted EBITDA of €65.8 million and a margin of 26.8%. A notable 21% backlog increase to approximately €1.01 billion underscores strong future demand. The company raised its 2022 guidance, citing favorable currency effects amidst ongoing inflationary pressures.
Stevanato Group has partnered with Gerresheimer AG to launch the EZ-fill Smart™, a new Ready-To-Use (RTU) vial platform. This innovation aims to enhance drug packaging quality, reduce total cost of ownership (TCO), and decrease lead times. Key features include increased automation, no glass-to-glass contact, and an environmentally friendly sterilization method. The platform is set for commercial availability in early 2024. The collaboration responds to a growing demand for RTU vials, positioning itself as the next industry standard in pharmaceutical packaging.
Stevanato Group (NYSE: STVN) has announced a non-exclusive agreement with DWK Life Sciences to distribute its EZ-fill® Ready-to-Use (RTU) solutions. This collaboration aims to enhance the distribution of EZ-fill® products, which include vials and cartridges specifically designed for pharmaceutical use. The EZ-fill® technology has been widely adopted, with over 250 installations in the last 12 years, ensuring quality improvements and reduced costs. The partnership is expected to leverage DWK’s extensive laboratory network to expand Stevanato's market reach.
Stevanato Group S.p.A (NYSE: STVN) will release its third-quarter 2022 financial results on November 8, 2022, at 6:30 a.m. (ET). The company will host a conference call and webcast to discuss these results at 8:30 a.m. (ET) on the same day, which will include a slide presentation available on its Investor Relations webpage.
Participants can pre-register for immediate access, while those unable to do so may dial in directly. The archived webcast will be accessible for three months post-event.
Bexson Biomedical and Stevanato Group have been jointly awarded the PDA's 2022 Drug Delivery Innovation Partnership Award for their collaboration on the On Body Delivery System (OBDS). This recognition highlights their innovative work in optimizing drug delivery solutions for non-opioid pain management, particularly with Bexson's SEVALENT™ formulation technology. The award was presented at the PDA conference in Palm Springs, CA on October 18, 2022. Bexson’s lead therapy, BB106, targets a $36 billion market.
Stevanato Group (NYSE: STVN) announced its participation in the Bank of America Global Healthcare Conference on September 15, 2022, at 9:05 a.m. BST in London. The event highlights the company's role as a leading provider of drug containment and delivery solutions. Interested investors can access a webcast via the company's website under the 'News & Events' section. Founded in 1949, Stevanato Group provides integrated solutions for the pharmaceutical and life sciences industries, focusing on innovation and engineering excellence.
Stevanato Group (NYSE: STVN) and Gerresheimer AG have announced their collaboration to develop a new Ready-To-Use (RTU) vial solution based on Stevanato's EZ-fill® technology. This initiative aims to enhance quality, efficiency, and reduce the total cost of ownership for pharmaceutical companies. The partnership addresses the rising demand for RTU vials, with a focus on standardizing fill-finish operations. The new solution will significantly lower particle load, bolstering overall quality. The platform will be showcased at the CPhI Worldwide in Frankfurt in November 2022.